Recent

% | $
Quotes you view appear here for quick access.

Primo Water Corporation Message Board

thanksfather1 37 posts  |  Last Activity: 6 hours ago Member since: Aug 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    APPROVAL !!!!!!!

    by messageman3 6 hours ago
    thanksfather1 thanksfather1 6 hours ago Flag

    Russell 3000® Index - Additions

    LIPOCINE INC LPCN Health Care

    Sentiment: Strong Buy

  • Reply to

    The Letter

    by thanksfather1 Jun 1, 2016 4:14 PM
    thanksfather1 thanksfather1 Jun 16, 2016 4:01 PM Flag

    loko, remember all your great DD and your own saying " ATRS Rocks.........!!!!

    Technically speaking we have a perfect cup and handle, if the bio market improves as it should, for we are due for a rally, and ATRS brings some good news on the improvement of Otrexup sales, Summa Launch, and some EPI news we are ready to go higher, and break the 1.25 resistance and pass that.

    Peace

    Sentiment: Strong Buy

  • Reply to

    The Letter

    by thanksfather1 Jun 1, 2016 4:14 PM
    thanksfather1 thanksfather1 Jun 14, 2016 4:06 PM Flag

    Thanks be to God, we should all Live and enjoy reading Nasdaq letter in the comming days.

    Sentiment: Strong Buy

  • thanksfather1 thanksfather1 Jun 8, 2016 6:25 PM Flag

    Here's Why You Should Watch For Movement In Lipocine Tomorrow

    Traders interested in biotech news should watch out for headlines tomorrow out of Lipocine Inc (NASDAQ: LPCN).

    Lipocine has been developing a new treatment for hypogonadism, a disease causing a lack of endogenous testosterone. In anticipation of the drug LPCN-1021 nearing its PDUFA date, an expert will be discussing the market potential of this new testosterone-deficiency treatment with Slingshot Insights at 12:30 p.m. ET.

    Why You Should Care
    In March 2015, the FDA set new guidelines regarding treatment of low testosterone, which stated that men experiencing low testosterone levels due to natural aging should not receive treatment. The main form of treatment for male hypogonadism is simply hormone replacement, and Lipocine's LPCN-1021 met its Phase 3 trial endpoint with over 75 percent of subjects within the age-appropriate average levels of testosterone. The PDUFA date for LPCN-1021, the FDA's deadline to approve the drug, is June 28.

    What Will Be Discussed
    The expert interview will explore the market potential for LPCN-1021, looking into the scope of patients eligible for this treatment, and how it compares to conventional treatments for hypogonadism. The information regarding the target patient population and which patients are suitable for the label could cause some volatility in the stock.

    The expert, a researcher who has been studying the relationship between sex hormones and heart disease and has led the investigation of new options for testosterone replacement therapies, will discuss the scope and demand for treatment of this issue.

    Sentiment: Strong Buy

  • Reply to

    Picture Perfect

    by thanksfather1 Jun 8, 2016 9:44 AM
    thanksfather1 thanksfather1 Jun 8, 2016 1:40 PM Flag

    affirmed, tha's where I see the opportunity, and I see a clear path to profitability, it is taking and will take more time than expected, but God willing it will come. The path is clear, increase Otrexup sales, launch Summa, sign a deal for QST, and keep milking the pipeline. And God willing some EPI good news and forget about it, we are off to the races.

    Sentiment: Strong Buy

  • Reply to

    Picture Perfect

    by thanksfather1 Jun 8, 2016 9:44 AM
    thanksfather1 thanksfather1 Jun 8, 2016 12:37 PM Flag

    affirmed, I think ATRS fundamentals are as great as affirmed at the Belmont Stakes in 78.

    Sentiment: Strong Buy

  • Reply to

    Picture Perfect

    by thanksfather1 Jun 8, 2016 9:44 AM
    thanksfather1 thanksfather1 Jun 8, 2016 11:10 AM Flag

    batter, God willing we shall do it this time and get that Nasdaq letter.

    Peace

    Sentiment: Strong Buy

  • Reply to

    Picture Perfect

    by thanksfather1 Jun 8, 2016 9:44 AM
    thanksfather1 thanksfather1 Jun 8, 2016 11:08 AM Flag

    namm, when I look at that presentation I can´t believe we sit at a 160 million market cup. I expect and upgrade to BUY from Jefferies or someone else-

    Sentiment: Strong Buy

  • Reply to

    Picture Perfect

    by thanksfather1 Jun 8, 2016 9:44 AM
    thanksfather1 thanksfather1 Jun 8, 2016 10:16 AM Flag

    Support at 0.70, 0.80 and now we may hold 1, to complete the handle and then God willing we shall live and see ATRS rocket pass 1.20 1.25

    Excelent presentation Page 5 for the Jefferies conf. today.

    Sentiment: Strong Buy

  • thanksfather1 by thanksfather1 Jun 8, 2016 9:44 AM Flag

    Cup and handle formation. Ready for a move up to break the $ 1.20 and $ 1.25 resistence.

    Sentiment: Strong Buy

  • thanksfather1 by thanksfather1 Jun 6, 2016 5:36 PM Flag

    ARTX
    Kutler Jon B
    Chairman of the Board Jun 03 Buy 2.70 205 554 Jun 06 10:21 AM

    ARTX
    Kutler Jon B
    Chairman of the Board Jun 02 Buy 2.66 1,333 3,546 Jun 06 10:21 AM

    ARTX
    Kutler Jon B
    Chairman of the Board Jun 01 Buy 2.68 37,641 100,948 Jun 06 10:21 AM

    Sentiment: Strong Buy

  • thanksfather1 thanksfather1 Jun 2, 2016 6:35 PM Flag

    Loko, God willing we are going higher tomorrow, looking forward to the break of $ 1.16. we are down in AF hours at $ 1.08 on only 10 shares yes 10 shares jajajaj, just to paint the tape. Thanks again for sharing all your DD.

    Peace

    Sentiment: Strong Buy

  • Reply to

    Closes right at resistance

    by affirmed_78 Jun 1, 2016 5:38 PM
    thanksfather1 thanksfather1 Jun 1, 2016 5:52 PM Flag

    The 2nd cup and handle, the breakout, the volume, the positive news ahead, conference by AMAG on the 7th and ATRS on the 8th, shorts covering, all positives, I say we are going Higher, The next resistance to break is $ 1.16. And any surprise news and we are going parabolic.

    Sentiment: Strong Buy

  • thanksfather1 by thanksfather1 Jun 1, 2016 4:14 PM Flag

    God willing, very soon we shall read this letter.

    ATRS announces that it has received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it has regained full compliance with NASDAQ's minimum bid price continued listing requirement.

    The letter, noted that the closing bid price of ATRS common stock has been at $1.00 per share or higher for the last 10 consecutive business days, from . Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

    God Bless you All

    Peace

    Sentiment: Strong Buy

  • thanksfather1 thanksfather1 May 25, 2016 10:54 AM Flag

    Loko, for at least the past five years or more you have been the only one providing the best information. God willing this time we are heading above $1 and for more than 10 days. God Bless you Loko!!! Thanks for everything you have share.

    Sentiment: Strong Buy

  • thanksfather1 thanksfather1 May 25, 2016 9:33 AM Flag

    Up

    Sentiment: Strong Buy

  • Date:
    April 28, 2016
    Source:
    Tulane University
    Summary:
    Researchers have identified a key hormone-signaling pathway that explains why men with low testosterone are at greater risk for developing Type 2 diabetes, according to a new study

    Doctors have long known that men with low testosterone are at greater risk for developing type 2 diabetes. For the first time, researchers have identified how testosterone helps men regulate blood sugar by triggering key signaling mechanisms in islets, clusters of cells within the pancreas that produce insulin. The findings, co-authored by Tulane University researchers, are published in the journal Cell Metabolism.

    The study could help identify new treatments for type 2 diabetes in the large number of men with low testosterone due to age or prostate cancer therapies.

    "We have found the cause -- and a potential treatment pathway -- for type 2 diabetes in testosterone-deficient men," says senior author Dr. Franck Mauvais-Jarvis, Price-Goldsmith professor in the Department of Medicine at Tulane University School of Medicine. "Our study shows that testosterone is an anti-diabetic hormone in men. If we can modulate its action without side effects, it is a therapeutic avenue for type 2 diabetes."

    Article continues..

    Sentiment: Strong Buy

  • "In fact, the researchers found not only that men prescribed testosterone replacement therapy (TRT) for longer than a year showed no overall increase in risk of developing prostate cancer, but that if anything, their risk for aggressive disease was 50 percent lower than equivalent men not prescribed TRT."

    Sentiment: Strong Buy

  • Reply to

    Revenue Beat, Earnings Miss

    by brunoq_78242 May 9, 2016 7:28 AM
    thanksfather1 thanksfather1 May 9, 2016 7:56 AM Flag

    in thousands.

    OTREXUP™

    $ 3,310

    Compare to $ 3.307 last quarter

    I dont´t think we reach the 10.000 Trx mark yet

    Sentiment: Strong Buy

  • Reply to

    This Stinks

    by florestan1770 May 4, 2016 3:03 PM
    thanksfather1 thanksfather1 May 4, 2016 4:08 PM Flag

    ok, game over, it hit the rim. No problem, lets re group and start again, we have a game tomorrow and a full six month season, lets build a base around this 0.90 area and the next leg up lets overcome 1 forever. I personally do not like reverse splits. The only reverse split I liked was priceline back in 2003.

    Dios los Bendiga a todos. Y a no perder la Fe y la Esperanza after you have done your good dd

    Sentiment: Strong Buy

PRMW
10.61-0.28(-2.57%)Jun 24 4:00 PMEDT